Am J Psychiatry 159:133-135, January 2002
© 2002 American Psychiatric Association
Elevation of Prolactin Levels by Atypical Antipsychotics
Peter Turrone, B.A.(Sp.H.), M.Sc.,
Shitij Kapur, M.D., Ph.D., F.R.C.P.C.,
Mary V. Seeman, M.D., F.R.C.P.C., and
Alastair J. Flint, M.D., F.R.C.P.C.
OBJECTIVE: Atypical antipsychotics are thought not to elevate prolactin levels. The authors examined data suggesting that atypical antipsychotics do elevate prolactin levels but more transiently than typical antipsychotics. METHOD: Prolactin levels in 18 male patients with schizophrenia who were receiving atypical antipsychotics were monitored over the 24-hour period following administration of their daily oral dose of risperidone, olanzapine, or clozapine. RESULTS: The baseline prolactin levels in patients receiving risperidone (mean=27 ng/ml, SD=14) were abnormally high, but baseline prolactin levels in patients receiving olanzapine (mean=9 ng/ml, SD=5) and clozapine (mean=9 ng/ml, SD=5) were not high. All three atypical antipsychotics caused a doubling of prolactin levels over baseline levels 6 hours after medication administration. CONCLUSIONS: These data suggest that these atypical antipsychotics raise prolactin levels, although the increases with olanzapine did not reach statistical significance. This suggests that the differences in the effects on prolactin levels of atypical and typical antipsychotics are not categorical but lie in the degree and duration of dose-induced prolactin elevation, attributable to the differential binding properties of each drug on pituitary dopamine D2 receptors.
This article has been cited by other articles:
|
|
|
|
 
C. Manning and T. Stickley
Childhood abuse and psychosis; a critical review of the literature
Journal of Research in Nursing,
November 1, 2009;
14(6):
531 - 547.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. J. Millan, F. Loiseau, A. Dekeyne, A. Gobert, G. Flik, T. I. Cremers, J.-M. Rivet, D. Sicard, R. Billiras, and M. Brocco
S33138 (N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenyl-acetamide), a Preferential Dopamine D3 versus D2 Receptor Antagonist and Potential Antipsychotic Agent: III. Actions in Models of Therapeutic Activity and Induction of Side Effects
J. Pharmacol. Exp. Ther.,
March 1, 2008;
324(3):
1212 - 1226.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Fitzgerald and T. G Dinan
Prolactin and dopamine: What is the connection? A Review Article
J Psychopharmacol,
March 1, 2008;
22(2_suppl):
12 - 19.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. Bushe, M. Shaw, and R. C Peveler
A review of the association between antipsychotic use and hyperprolactinaemia
J Psychopharmacol,
March 1, 2008;
22(2_suppl):
46 - 55.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L. Citrome
Current guidelines and their recommendations for prolactin monitoring in psychosis
J Psychopharmacol,
March 1, 2008;
22(2_suppl):
90 - 97.
[Abstract]
[PDF]
|
|
|
|
|
|
|
N. Ben-Jonathan, C. R. LaPensee, and E. W. LaPensee
What Can We Learn from Rodents about Prolactin in Humans?
Endocr. Rev.,
February 1, 2008;
29(1):
1 - 41.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-C. Shim, J.-G. K. Shin, D. L. Kelly, D.-U. Jung, Y.-S. Seo, K.-H. Liu, J.-H. Shon, and R. R. Conley
Adjunctive Treatment With a Dopamine Partial Agonist, Aripiprazole, for Antipsychotic-Induced Hyperprolactinemia: A Placebo-Controlled Trial
Am J Psychiatry,
September 1, 2007;
164(9):
1404 - 1410.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Rasmussen, M. J. Benvenga, F. P. Bymaster, D. O. Calligaro, I. R. Cohen, J. F. Falcone, S. K. Hemrick-Luecke, F. M. Martin, N. A. Moore, L. K. Nisenbaum, et al.
Preclinical Pharmacology of FMPD [6-Fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: A Potential Novel Antipsychotic with Lower Histamine H1 Receptor Affinity Than Olanzapine
J. Pharmacol. Exp. Ther.,
December 1, 2005;
315(3):
1265 - 1277.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. Molitch
Medication-Induced Hyperprolactinemia
Mayo Clin. Proc.,
August 1, 2005;
80(8):
1050 - 1057.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. G Robinson, M. G Woerner, H. M Delman, and J. M Kane
Pharmacological Treatments for First-Episode Schizophrenia
Schizophr Bull,
July 1, 2005;
31(3):
705 - 722.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Knegtering, P. Baselmans, S. Castelein, F. Bosker, R. Bruggeman, and R. J. van den Bosch
Predominant Role of the 9-Hydroxy Metabolite of Risperidone in Elevating Blood Prolactin Levels
Am J Psychiatry,
May 1, 2005;
162(5):
1010 - 1012.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Dunkley and M. A. Reveley
Successful treatment of refractory schizophrenia with combined olanzapine and quetiapine in a patient with a prolactin secreting pituitary microadenoma
J Psychopharmacol,
January 1, 2005;
19(1):
97 - 101.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. M. Moresco, R. Cavallaro, C. Messa, D. Bravi, C. Gobbo, L. Galli, G. Lucignani, C. Colombo, G. Rizzo, I. Velona, et al.
Cerebral D2 and 5-HT2 Receptor occupancy in Schizophrenic Patients Treated with Olanzapine Or Clozapine
J Psychopharmacol,
September 1, 2004;
18(3):
355 - 365.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. R. Marder, S. M. Essock, A. L. Miller, R. W. Buchanan, D. E. Casey, J. M. Davis, J. M. Kane, J. A. Lieberman, N. R. Schooler, N. Covell, et al.
Physical Health Monitoring of Patients With Schizophrenia
Am J Psychiatry,
August 1, 2004;
161(8):
1334 - 1349.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Mamo, S. Kapur, C. M. Shammi, G. Papatheodorou, S. Mann, F. Therrien, and G. Remington
A PET Study of Dopamine D2 and Serotonin 5-HT2 Receptor Occupancy in Patients With Schizophrenia Treated With Therapeutic Doses of Ziprasidone
Am J Psychiatry,
May 1, 2004;
161(5):
818 - 825.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Meaney and V. O'Keane
Reduced Bone Mineral Density in Patients with Schizophrenia Receiving Prolactin Raising Anti-Psychotic Medication
J Psychopharmacol,
December 1, 2003;
17(4):
455 - 458.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. E. Keck Jr., R. Marcus, S. Tourkodimitris, M. Ali, A. Liebeskind, A. Saha, G. Ingenito, and the Aripiprazole Study Group
A Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of Aripiprazole in Patients With Acute Bipolar Mania
Am J Psychiatry,
September 1, 2003;
160(9):
1651 - 1658.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. ALEXIADIS, D. WHITEHORN, H. WOODLEY, and L. KOPALA
Prolactin Elevation With Quetiapine
Am J Psychiatry,
September 1, 2002;
159(9):
1608 - 1609.
[Full Text]
|
|
|
|
|
|
|
S. Kapur, X. Langlois, P. Vinken, A. A. H. P. Megens, R. De Coster, and J. S. Andrews
The Differential Effects of Atypical Antipsychotics on Prolactin Elevation Are Explained by Their Differential Blood-Brain Disposition: A Pharmacological Analysis in Rats
J. Pharmacol. Exp. Ther.,
September 1, 2002;
302(3):
1129 - 1134.
[Abstract]
[Full Text]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2002
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
